Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) has earned an average recommendation of “Hold” from the twenty brokerages that are presently covering the firm, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $21.06.

Several brokerages recently weighed in on VRX. Deutsche Bank restated a “buy” rating on shares of Valeant Pharmaceuticals in a report on Friday, June 29th. Mizuho restated a “buy” rating and issued a $31.00 price objective on shares of Valeant Pharmaceuticals in a report on Friday, June 29th. TD Securities lowered shares of Valeant Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 price objective on the stock. in a report on Friday, June 22nd. HC Wainwright restated a “hold” rating and issued a $20.00 price objective on shares of Valeant Pharmaceuticals in a report on Wednesday, June 20th. Finally, Barclays upgraded shares of Valeant Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $20.00 to $34.00 in a report on Wednesday, June 6th.

NYSE VRX traded down $0.83 during trading hours on Tuesday, hitting $23.40. The company’s stock had a trading volume of 6,571,593 shares, compared to its average volume of 6,356,695. Valeant Pharmaceuticals has a twelve month low of $10.94 and a twelve month high of $27.79. The firm has a market capitalization of $8.16 billion, a P/E ratio of 6.11, a P/E/G ratio of 0.35 and a beta of -0.38. The company has a debt-to-equity ratio of 5.59, a current ratio of 1.18 and a quick ratio of 0.92.

Institutional investors and hedge funds have recently bought and sold shares of the business. Envestnet Asset Management Inc. raised its holdings in Valeant Pharmaceuticals by 189.4% in the first quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after purchasing an additional 3,921 shares during the period. Bedel Financial Consulting Inc. acquired a new stake in Valeant Pharmaceuticals in the second quarter worth $116,000. Signaturefd LLC raised its holdings in Valeant Pharmaceuticals by 78.6% in the second quarter. Signaturefd LLC now owns 5,248 shares of the specialty pharmaceutical company’s stock worth $122,000 after purchasing an additional 2,309 shares during the period. Amussen Hunsaker Associates LLC acquired a new stake in Valeant Pharmaceuticals in the second quarter worth $130,000. Finally, Assetmark Inc. raised its holdings in Valeant Pharmaceuticals by 409.4% in the first quarter. Assetmark Inc. now owns 11,498 shares of the specialty pharmaceutical company’s stock worth $183,000 after purchasing an additional 9,241 shares during the period. Institutional investors own 46.95% of the company’s stock.

About Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Recommended Story: Technical Analysis

Analyst Recommendations for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.